BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36765951)

  • 1. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
    Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
    Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
    Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
    Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
    Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
    Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
    Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
    J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
    Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
    Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
    Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
    BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
    Ulase D; Behrens HM; Röcken C
    Virchows Arch; 2024 May; ():. PubMed ID: 38748262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell-mediated immune surveillance in cancer: Role of tumor microenvironment.
    Saadh MJ; Rasulova I; Khalil M; Farahim F; Sârbu I; Ciongradi CI; Omar TM; Alhili A; Jawad MJ; Hani T; Ali T; Lakshmaiya N
    Pathol Res Pract; 2024 Feb; 254():155120. PubMed ID: 38280274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
    Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
    Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study.
    Hu Q; Wang Y; Yao S; Mao Y; Liu L; Li Z; Chen Y; Zhang S; Li Q; Zhao Y; Fan X; Cui Y; Zhao K; Liu Z
    Cancer Res Commun; 2023 Jun; 3(6):1057-1066. PubMed ID: 37377615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.
    Vidriales MB; Orfao A; López-Berges MC; González M; Hernandez JM; Ciudad J; López A; Moro MJ; Martínez M; San Miguel JF
    Ann Hematol; 1993 Nov; 67(5):217-22. PubMed ID: 7694663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
    Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
    Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Lymphocytes Reflect the Local Immune Response in Patients with Colorectal Carcinoma.
    Waidhauser J; Nerlinger P; Sommer F; Wolf S; Eser S; Löhr P; Rank A; Märkl B
    Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Tim‑3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer.
    Wang Y; Sun J; Gao W; Song B; Shao Q; Zhao L; Zhang Y; Wang Q; Zhang Y; Qu X
    Mol Med Rep; 2017 Jun; 15(6):3810-3818. PubMed ID: 28440449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
    Yuen MF; Norris S
    Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion.
    Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
    Lung; 2019 Feb; 197(1):53-60. PubMed ID: 30523401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
    Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
    Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.